Safe and well tolerated75% of patients free of tumor recurrence up to 24 weeks and with stronger IFN-γ-producing CTL responses against AFP, MAGE-1, and/or GPC-3 antigensLonger median TTP for patients with vaccination than patients without vaccination (36.6 months versus 11.8 moths). This evidence concerns the gene IFNG and neoplasm.